On Monday, UroGen Pharma cleared an important performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 81, up from 65 the day before.
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating of above 80 as they begin their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
While the stock is not near an ideal entry right now, see if it is able to form and break out of a proper base.
The company reported 0% EPS growth in its most recent report. Revenue gains came in at 9%.
UroGen Pharma holds the No. 191 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
